Biogen Inc. (BIIB) exhibits 75.7% gross margins and 6.4% return on invested capital within Health Care (Biotechnology: Biological Products (No Diagnostic Substances)), balanced against a 22.3x enterprise multiple and 7.2% implied options volatility.
Sustained 75.7% gross profitability converts into 15.9% operating margin and 6.4% ROIC, outpacing sector cost of capital.
ROIC: 6.4% // GM: 75.7%YoY revenue trajectory of +2.2% paired with 5.56% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +2.2% // FCF YLD: 5.56%Altman Z-Score of 3.70 and Piotroski F-Score of 7/9 indicate low near-term refinancing stress.
ALTMAN Z: 3.70 // F-SCORE: 7/9Trading at 28.5x trailing P/E (26.5x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 28.5x // EV/EBITDA: 22.3xOptions market prices a ±7.2% implied move with a 0.84 put/call ratio around $245.00 max pain.
IMPL MOVE: ±7.2% // P/C: 0.84Elevated industry capital intensity and customer concentration in Biotechnology: Biological Products (No Diagnostic Substances) require continuous execution to defend 13.1% net margins.
NET MARGIN: 13.1% // D/E: 0.26x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for BIIB & activate live FRED threshold breach alerts.